FibroBiologics (NASDAQ:FBLG) Receives “Buy” Rating from D. Boral Capital

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reiterated by D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $15.00 price objective on the stock.

Several other research firms have also weighed in on FBLG. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a research report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of FibroBiologics in a research report on Friday, September 12th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, FibroBiologics currently has a consensus rating of “Moderate Buy” and an average target price of $12.33.

FibroBiologics Price Performance

NASDAQ FBLG traded up $0.01 on Thursday, hitting $0.36. 421,435 shares of the company were exchanged, compared to its average volume of 502,431. FibroBiologics has a twelve month low of $0.28 and a twelve month high of $2.98. The firm has a market capitalization of $18.27 million, a P/E ratio of -0.74 and a beta of -0.72. The company’s 50 day moving average price is $0.45 and its 200-day moving average price is $0.62.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings results on Friday, October 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03). As a group, equities analysts expect that FibroBiologics will post -0.53 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of FBLG. AQR Capital Management LLC acquired a new position in FibroBiologics during the first quarter worth $29,000. XTX Topco Ltd increased its holdings in shares of FibroBiologics by 160.0% during the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock valued at $29,000 after acquiring an additional 28,276 shares during the last quarter. Ethos Financial Group LLC raised its stake in shares of FibroBiologics by 100.0% in the 2nd quarter. Ethos Financial Group LLC now owns 48,848 shares of the company’s stock valued at $30,000 after acquiring an additional 24,424 shares in the last quarter. Nuveen LLC acquired a new position in FibroBiologics during the first quarter valued at approximately $31,000. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of FibroBiologics in the second quarter valued at approximately $37,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.